Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials of psychedelics such as LSD for depression and anxiety in terminally ill patients have been conducted. In the 21st century, revived and accelerated efforts to promote the proper use of psychedelics in the medical field have led to increasingly...
Abstract Background Only 18-45% of individuals with treatment-resistant depression (TRD) respond to intravenous ketamine therapy. Although some neurobiological predictors of response to ketamine have been reported, none have been consistently replicated across multiple studies. The imbalance between glutamatergic excitatory and GABAergic inhibitory neurotransmissions is implicated in the...